GO
| HSI1 | 26,347.91 | 0.00 | -- |
| HSCEI1 | 8,882.37 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
HENGRUI PHARMA, BMS Clinch Global Strategic Collaboration and License Agreement
2026-05-12 12:20:36 HENGRUI PHARMA (01276.HK) announced that it had entered into global strategic collaboration and license agreements with Bristol-Myers Squibb Company (BMS)(BMY.US) to advance a portfolio of 13 early stage programs in oncology, hematology and immunology. Under the agreement, BMS will pay HENGRUI PHARMA up to USD950 million, including a USD600 million upfront payment, a USD175 million first anniversary payment, and a second contingent anniversary payment of USD175 million in 2028. The potential total value of the agreements is up to approximately USD15.2 billion, including the exercise of available options for the joint discovery programs and the achievement of applicable development, regulatory, and commercial milestones for all programs. ~ AASTOCKS Financial News Website: www.aastocks.com | |